Gregorio

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Retrieved on: 
Tuesday, March 12, 2024
Principal, GP2, Faculty, Breast cancer, Gregorio, Immunotherapy, Disease, Patient, Knowledge, GM-CSF, Research, Hospital, Observation, Pi, Cancer, Death, Teaching hospital, Baylor College of Medicine, ECIS, Complutense University of Madrid, Woman, Prognosis, Book, Vaccine, Map

The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.

Key Points: 
  • The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
  • These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week.
  • Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
  • Breast cancer is the leading cause of death in women between the ages 35-45 in Spain with 6,836 deaths in 2022.

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer

Retrieved on: 
Saturday, October 21, 2023
FDA, SCLC, Metastasis, Gregorio, ESMO, Food, Pembrolizumab, European Society for Medical Oncology, US Foods, American Society of Clinical Oncology, Research, HIV disease progression rates, Carcinoma, Society, Lurbinectedin, Neoplasm, Ecosystem, Cancer, Congress, Breast cancer, Oncology, Immunotherapy, TACSTD2, Patient, Prognosis, ASCO, Medical imaging, Pharmaceutical industry, Medical device

These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.

Key Points: 
  • These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.
  • A total of 28 patients with SCLC who had not previously received immunotherapy were enrolled in the LUPER trial.
  • In the first of the translational studies presented by MEDSIR at ESMO, we analyzed the expression levels of the Trop-2 protein in tumor samples from patients with HER2-positive early breast cancer.
  • The HER2DX® genomic test may prove to be a valuable tool to guide healthcare professionals and patients in personalizing treatment for HER2-positive early breast cancer.